PepGen (PEPG) Competitors

$1.78 +0.10 (+5.95%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$1.80 +0.02 (+1.40%)

As of 07:48 AM Eastern

PEPG vs. EPRX, FDMT, CADL, KMDA, and RGNX

Should you buy PepGen stock or one of its competitors? MarketBeat compares PepGen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PepGen include Eupraxia Pharmaceuticals (EPRX), 4D Molecular Therapeutics (FDMT), Candel Therapeutics (CADL), Kamada (KMDA), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry.

How does PepGen compare to Eupraxia Pharmaceuticals?

PepGen (NASDAQ:PEPG) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Eupraxia Pharmaceuticals had 2 more articles in the media than PepGen. MarketBeat recorded 7 mentions for Eupraxia Pharmaceuticals and 5 mentions for PepGen. PepGen's average media sentiment score of 1.03 beat Eupraxia Pharmaceuticals' score of 0.41 indicating that PepGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PepGen presently has a consensus target price of $11.60, indicating a potential upside of 551.69%. Eupraxia Pharmaceuticals has a consensus target price of $15.00, indicating a potential upside of 98.68%. Given PepGen's higher probable upside, equities analysts plainly believe PepGen is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$2.41	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.03	N/A

58.0% of PepGen shares are held by institutional investors. 1.3% of PepGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

PepGen's return on equity of -60.68% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-60.68%	-49.69%
Eupraxia Pharmaceuticals	N/A	-137.95%	-66.02%

PepGen has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market.

Summary

PepGen beats Eupraxia Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does PepGen compare to 4D Molecular Therapeutics?

PepGen (NASDAQ:PEPG) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, 4D Molecular Therapeutics had 12 more articles in the media than PepGen. MarketBeat recorded 17 mentions for 4D Molecular Therapeutics and 5 mentions for PepGen. PepGen's average media sentiment score of 1.03 beat 4D Molecular Therapeutics' score of 0.19 indicating that PepGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
4D Molecular Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

PepGen presently has a consensus target price of $11.60, indicating a potential upside of 551.69%. 4D Molecular Therapeutics has a consensus target price of $29.88, indicating a potential upside of 185.89%. Given PepGen's higher possible upside, research analysts clearly believe PepGen is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

PepGen has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-60.68%	-49.69%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

58.0% of PepGen shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 1.3% of PepGen shares are held by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

PepGen has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.77, indicating that its stock price is 177% more volatile than the broader market.

PepGen has higher earnings, but lower revenue than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$2.41	N/A
4D Molecular Therapeutics	$85.21M	6.41	-$140.11M	-$2.57	N/A

Summary

4D Molecular Therapeutics beats PepGen on 8 of the 14 factors compared between the two stocks.

How does PepGen compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Candel Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.71	N/A
PepGen	N/A	N/A	-$89.65M	-$2.41	N/A

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by company insiders. Comparatively, 1.3% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Candel Therapeutics and Candel Therapeutics both had 5 articles in the media. PepGen's average media sentiment score of 1.03 beat Candel Therapeutics' score of 0.57 indicating that PepGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PepGen	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Candel Therapeutics' return on equity of -51.44% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-51.44%	-36.31%
PepGen	N/A	-60.68%	-49.69%

Candel Therapeutics currently has a consensus target price of $18.00, indicating a potential upside of 101.34%. PepGen has a consensus target price of $11.60, indicating a potential upside of 551.69%. Given PepGen's stronger consensus rating and higher probable upside, analysts clearly believe PepGen is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Candel Therapeutics has a beta of -0.59, indicating that its share price is 159% less volatile than the broader market. Comparatively, PepGen has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market.

Summary

Candel Therapeutics and PepGen tied by winning 6 of the 12 factors compared between the two stocks.

How does PepGen compare to Kamada?

PepGen (NASDAQ:PEPG) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Kamada has a net margin of 11.19% compared to PepGen's net margin of 0.00%. Kamada's return on equity of 7.72% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-60.68%	-49.69%
Kamada	11.19%	7.72%	5.39%

58.0% of PepGen shares are owned by institutional investors. Comparatively, 20.4% of Kamada shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Comparatively, 36.1% of Kamada shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Kamada has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$2.41	N/A
Kamada	$180.46M	2.50	$20.20M	$0.35	22.46

PepGen has a beta of 2.01, indicating that its stock price is 101% more volatile than the broader market. Comparatively, Kamada has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

PepGen currently has a consensus price target of $11.60, indicating a potential upside of 551.69%. Kamada has a consensus price target of $13.00, indicating a potential upside of 65.39%. Given PepGen's higher probable upside, equities research analysts clearly believe PepGen is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Kamada had 5 more articles in the media than PepGen. MarketBeat recorded 10 mentions for Kamada and 5 mentions for PepGen. PepGen's average media sentiment score of 1.03 beat Kamada's score of -0.28 indicating that PepGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kamada	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Kamada beats PepGen on 10 of the 15 factors compared between the two stocks.

How does PepGen compare to REGENXBIO?

REGENXBIO (NASDAQ:RGNX) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

PepGen has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	3.04	-$193.88M	-$3.76	N/A
PepGen	N/A	N/A	-$89.65M	-$2.41	N/A

PepGen has a net margin of 0.00% compared to REGENXBIO's net margin of -113.75%. PepGen's return on equity of -60.68% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-113.75%	-103.12%	-37.83%
PepGen	N/A	-60.68%	-49.69%

REGENXBIO has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, PepGen has a beta of 2.01, meaning that its stock price is 101% more volatile than the broader market.

In the previous week, REGENXBIO had 1 more articles in the media than PepGen. MarketBeat recorded 6 mentions for REGENXBIO and 5 mentions for PepGen. PepGen's average media sentiment score of 1.03 beat REGENXBIO's score of -0.04 indicating that PepGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PepGen	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

REGENXBIO presently has a consensus price target of $27.50, indicating a potential upside of 173.90%. PepGen has a consensus price target of $11.60, indicating a potential upside of 551.69%. Given PepGen's higher possible upside, analysts clearly believe PepGen is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Comparatively, 1.3% of PepGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

PepGen beats REGENXBIO on 8 of the 15 factors compared between the two stocks.

Get PepGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PEPG vs. The Competition

Export

Metric	PepGen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$116.20M	$3.42B	$6.30B	$12.28B
Dividend Yield	N/A	2.30%	2.79%	5.30%
P/E Ratio	-1.02	18.67	21.03	25.58
Price / Sales	N/A	305.47	554.66	78.88
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	0.83	6.75	9.78	6.66
Net Income	-$89.65M	$24.11M	$3.55B	$333.63M
7 Day Performance	-0.56%	-0.53%	-0.52%	-0.12%
1 Month Performance	5.33%	0.34%	1.21%	3.93%
1 Year Performance	28.99%	78.62%	41.26%	36.07%

PepGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PEPG PepGen	3.8301 of 5 stars	$1.78 +6.0%	$11.60 +551.7%	+16.3%	$116.20M	N/A	N/A	30	Positive News Earnings Report Analyst Forecast Gap Down
EPRX Eupraxia Pharmaceuticals	2.3284 of 5 stars	$7.42 -6.0%	$15.00 +102.2%	+95.1%	$476.83M	N/A	N/A	29	Earnings Report
FDMT 4D Molecular Therapeutics	2.3522 of 5 stars	$9.44 +3.9%	$31.25 +231.0%	+219.6%	$475.18M	$85.21M	N/A	120	Earnings Report Analyst Revision
CADL Candel Therapeutics	3.9508 of 5 stars	$7.53 +16.4%	$18.00 +139.0%	+65.9%	$474.06M	N/A	N/A	60
KMDA Kamada	4.7345 of 5 stars	$8.29 +1.0%	$13.00 +56.8%	+14.1%	$472.12M	$180.46M	23.69	360	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PEPG) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PepGen (PEPG) Competitors

PEPG vs. EPRX, FDMT, CADL, KMDA, and RGNX

How does PepGen compare to Eupraxia Pharmaceuticals?

Summary

How does PepGen compare to 4D Molecular Therapeutics?

Summary

How does PepGen compare to Candel Therapeutics?

Summary

How does PepGen compare to Kamada?

Summary

How does PepGen compare to REGENXBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG vs. The Competition

PepGen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PepGen (PEPG) Competitors

PEPG vs. EPRX, FDMT, CADL, KMDA, and RGNX

How does PepGen compare to Eupraxia Pharmaceuticals?

Does the media favor PEPG or EPRX?

Do analysts rate PEPG or EPRX?

Which has better valuation and earnings, PEPG or EPRX?

Do institutionals & insiders believe in PEPG or EPRX?

Is PEPG or EPRX more profitable?

Which has more risk and volatility, PEPG or EPRX?

Summary

How does PepGen compare to 4D Molecular Therapeutics?

Does the media refer more to PEPG or FDMT?

Do analysts rate PEPG or FDMT?

Is PEPG or FDMT more profitable?

Do insiders and institutionals have more ownership in PEPG or FDMT?

Which has more volatility & risk, PEPG or FDMT?

Which has stronger valuation & earnings, PEPG or FDMT?

Summary

How does PepGen compare to Candel Therapeutics?

Which has better earnings & valuation, CADL or PEPG?

Do insiders & institutionals have more ownership in CADL or PEPG?

Does the media prefer CADL or PEPG?

Is CADL or PEPG more profitable?

Do analysts prefer CADL or PEPG?

Which has more volatility & risk, CADL or PEPG?

Summary

How does PepGen compare to Kamada?

Is PEPG or KMDA more profitable?

Do insiders & institutionals believe in PEPG or KMDA?

Which has better valuation and earnings, PEPG or KMDA?

Which has more risk and volatility, PEPG or KMDA?

Do analysts recommend PEPG or KMDA?

Does the media favor PEPG or KMDA?

Summary

How does PepGen compare to REGENXBIO?

Which has higher earnings and valuation, RGNX or PEPG?

Is RGNX or PEPG more profitable?

Which has more volatility & risk, RGNX or PEPG?

Does the media prefer RGNX or PEPG?

Do analysts rate RGNX or PEPG?

Do insiders and institutionals have more ownership in RGNX or PEPG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG vs. The Competition

PepGen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools